Hoth Therapeutics renamed itself Rocket One in May to make AI chips for satellites, two months after its auditor doubted it could survive. Its stock went from under $1 to nearly $2 on a licensed chip design that has not been built, the story-first pitch that cost SPAC buyers most of their money.
Reality
- Evidence55
- Adoption2
- Hype gap+75
- Incentives70
- Confidence55
New Constructs values Anthropic at $150 billion, less than a tenth of the roughly $2 trillion market cap discussed for its Nasdaq listing. The bear case rests on reported losses, and the price will depend on whether Anthropic's own revenue claims hold up in the prospectus.
Reality
- Evidence35
- Adoption45
- Hype gap+40
- Incentives70
- Confidence40
Brent Franson spent four years on Most Days, a mental-health app users liked but that could not win them cheaply, before shutting it in late 2024. His test for stopping rests on founder conviction, though the flaw he names, costly user acquisition, was measurable.
Reality
- Evidence28
- Adoption
- Insufficient
- Hype gap+12
- Incentives62
- Confidence35
Second-quarter revenue of $11.6 billion put Anthropic ahead of OpenAI for the first time. The IPO story that follows is about who can bill, not who benchmarks best.
Perspective Coverage
3 publishers
- Builder
- Builder 12%
- Operator
- Operator 21%
- Investor
- Investor 67%
Reality
- Evidence55
- Adoption68
- Hype gap+58
- Incentives78
- Confidence55
The figure Anthropic is expected to show IPO investors describes a pool 12.5 times the S&P 1500 tech sector's revenue. Its own 2028 forecast reaches about 0.67% of it.
Reality
- Evidence45
- Adoption33
- Hype gap+62
- Incentives85
- Confidence52